Day: October 30, 2025

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Apollo Commercial Real Estate Finance, Inc. (the “Company” or “ARI”) (NYSE: ARI) today reported results for the quarter and nine months ended September 30, 2025. Net income attributable to common stockholders per diluted share of common stock was $0.34 for the quarter ended September 30, 2025. Distributable Earnings (a non-GAAP financial measure defined below), and Distributable Earnings prior to realized loss on investments and realized gain on litigation settlement per diluted share of common stock was $0.30 and $0.23 for the quarter ended September 30, 2025, respectively. Commenting on third quarter 2025 performance, Stuart Rothstein, Chief Executive Officer and President of the Company, said: “With $1.0 billion of new loan originations during the quarter ARI continued to benefit from...

US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. “Our team continues to execute solidly across the three most important business verticals: diagnostics, therapeutics, and capital structure,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “In the fourth quarter,...

MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced its operating results for the three and nine months ended September 30, 2025. “Overall, third quarter results were in line with our expectations. Our coastal and more urban markets maintained their strong performance while our sunbelt properties continued to experience tradeoffs between rate and occupancy,” commented President and Chief Executive Officer Christopher P. Marr. “We are encouraged as operating trends continue to stabilize and are confident that our systems position us well to maximize long-term revenue within our highest-quality portfolio.” Key Highlights for the Third QuarterReported diluted earnings per share (“EPS”) attributable to the Company’s common shareholders of $0.36. Reported funds from operations (“FFO”), as adjusted,...

NASHVILLE, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the third quarter ended September 30, 2025. THIRD QUARTER 2025 HIGHLIGHTSGAAP Net Loss of $(0.17) per share, NAREIT FFO of $0.34 per share, Normalized FFO of $0.41 per share, and FAD of $116.9 million (payout ratio of 73%) Same store cash NOI growth of +5.4% was driven by 90 basis points of occupancy increase and tenant retention of 88.6% with +3.9% cash leasing spreads Increased 2025 guidance for Normalized FFO per share to $1.59 – $1.61 and same store cash NOI growth to 4.00% – 4.75% Third quarter lease executions totaled 1.6 million square feet including 441,000 square feet of new lease executions During the third quarter and through October, completed asset sales of $404 million through...

HONG KONG, Oct. 30, 2025 (GLOBE NEWSWIRE) — SAMFINE CREATION HOLDINGS GROUP LIMITED (Nasdaq: SFHG) (the “Company” or “Samfine”), a printing service provider headquartered in Hong Kong, today announced its unaudited financial results for the six months ended June 30, 2025. Overview:Revenue was HK$82.1 million (US$10.5 million) for the six months ended June 30, 2025, representing an increase of 0.2% from HK$81.9 million for the same period in 2024. Net loss was HK$8.5 million (US$1.1 million) for the six months ended June 30, 2025, as compared with a net income of HK$0.8 million for the same period in 2024.Six Months Ended June 30, 2025 Financial Results Revenue. Revenue remained relatively stable at HK$82,121,233 (US$10,461,437) for the six months ended June 30, 2025, representing a marginal increase of 0.2% compared to HK$81,934,259...

NEWARK, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) — Artesian Resources Corporation (Nasdaq: ARTNA), a leading provider on the Delmarva Peninsula of water and wastewater services, and a number of other related business services, today announced third quarter and year-to-date results for 2025.  Diluted net income per share increased to $0.68 in the third quarter and $1.81 year-to-date Net income increased $0.1 million (2.2%) in the third quarter and $2.1 million (12.9%) year-to-date Invested $40.5 million year-to-date in water and wastewater infrastructureThird Quarter Results Net income for the three months ended September 30, 2025 was $7.0 million, a $0.1 million, or 2.2%, increase compared to net income for the three months ended September 30, 2024. Diluted net income per share increased 3.0% to $0.68, compared to $0.66 for the...

MDST ETF Surpasses $150 million and Captured 30% of September Monthly Midstream ETF FlowsWEBs Partnership Launches Eleven New Sector ETFsPrivate Fund Raising Exceeds Expectations DALLAS, Oct. 30, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE: WHG) today reported third quarter 2025 earnings. Significant items included:Investment strategies beating their primary benchmarks included Income Opportunity, Multi-Asset Income, Alternative Income, Credit Opportunities, Real Estate Income and Tactical Growth. Income Opportunity and Multi-Asset Income each posted top quartile rankings vs. peers and Real Estate Income posted a top decile ranking. Quarterly revenues totaled $24.3 million vs. $23.1 million in the second quarter and $23.7 million a year ago. Income of $3.7 million compared with $1.0 million in the second quarter...

Company to Host Conference Call Today, October 30, at 4:30pm ET BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update. Q3 2025 and Recent Corporate Highlights   CORDStrom™ Platform:Announced successful completion of first two commercial pilot-scale manufacturing runs of CORDStrom™ at CGT Catapult in preparation of regulatory filings to seek approval of CORDStrom™ for recessive dystrophic epidemolysis bullosa (RDEB). CORDStrom™ is on target to file an MAA submission mid-2026, followed shortly thereafter...

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial HighlightsRevenue of $192.9 million, a 30.7% increase compared to third quarter 2024 Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024 Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025 Increased fiscal year 2025 guidance for revenue and adjusted EBITDA marginRecent Operational HighlightsThird quarter 2025 record quarterly revenue driven by continued momentum in core long-term continuous monitoring business, sustained demand...

Raises Full-year Guidance CHARLOTTE, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported results for the third quarter ended September 27, 2025. Third Quarter Highlights (amounts presented for continuing operations; all comparisons against the third quarter of 2024, unless otherwise noted)Revenue of $592.8 million, up 22.6% GAAP income from continuing operations of $63.1 million, up 24.0% GAAP EPS of $1.29, up 19.4% Adjusted EPS* of $1.84, up 32.4% Adjusted EBITDA* of $136.1 million, up 30.9%Raising 2025 Guidance (all comparisons against the full year 2024, unless otherwise noted)Maintaining revenue range of $2.225 to $2.275 billion, up ~13% year-on-year at the midpoint. Adjusted EBITDA* range of $495 to $515 million, up ~20% year-on-year at the midpoint...